Navigation Links
Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
Date:10/7/2008

SAN DIEGO, Oct. 7 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical company, today announced findings from its development of PROMETHEUS(R) IBS Diagnostic, the first and only blood test for irritable bowel syndrome (IBS). The findings suggest measurable differences in the expression of particular biomarkers in blood samples between IBS and non-IBS patients. The identification of these biomarkers, combined with a proprietary algorithm, led to the development of PROMETHEUS IBS Diagnostic. These findings were presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Orlando, Florida.

"PROMETHEUS IBS Diagnostic is an exciting advancement in the field of functional gastrointestinal disease," said Dr. Anthony Lembo, M.D., a gastroenterologist in the Division of Gastroenterology at Beth Israel Deaconess Medial Center and an Assistant Professor of Medicine at Harvard Medical School. "This test complements current symptom-based diagnostic practices by identifying patients with biomarker patterns consistent or inconsistent with IBS."

Following an extensive analysis of approximately 600 to 700 pathways, each containing hundreds of potential IBS biomarkers, Prometheus scientists identified 16 biomarkers that showed sufficient altered expression. The expression levels of these 16 biomarkers were then measured in a sample cohort of more than 1,700 patients and analyzed to reveal optimal IBS prediction with a final set of 10 biomarkers, including some that enable Prometheus' proprietary protection. These biomarkers are associated with one or more of the following pathways related to digestion: motility, brain-gut axis, neuronal regulation and immune function.

"IBS can be very difficult to definitively diagnose and is therefore often left untreated," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "PROMETHEUS IBS Diagnostic is the first in a series of tests we are developing for this complex syndrome. It provides physicians a valuable tool to help clarify or validate other clinical findings. This test further strengthens our growing portfolio of proprietary, high-value diagnostics and complementary pharmaceutical products."

IBS can be challenging to diagnose because it is a functional disease that is not associated with any visible abnormality and symptoms often overlap with other gastrointestinal conditions, such as inflammatory bowel disease, celiac disease and chronic functional constipation/diarrhea. Symptom-based criteria have been established to make a positive diagnosis of IBS; however, in practice the diagnosis of IBS is typically made through a process of elimination by determining the patient does not have other gastrointestinal diseases with similar symptoms.

About IBS

According to the National Institute of Diabetes and Digestive and Kidney Diseases, in 2007, almost 60 million, or 20%, of the U.S. population had symptoms of IBS, making it one of the most common disorders diagnosed by physicians. At least twice as many women as men are affected by IBS, a disorder characterized most commonly by cramping, abdominal pain, bloating, constipation and diarrhea. Although it significantly impairs health-related quality of life, unfortunately, many people suffer from IBS for almost 3 years before being properly diagnosed and treated. It is believed that up to 75% of people suffering from IBS are not receiving medical care for their symptoms, due in part to the current difficulties of diagnosing IBS.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is currently focused on the detection, diagnosis and treatment of gastrointestinal diseases and disorders in the United States. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary, high-value diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
2. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
3. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
4. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
5. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
6. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
7. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
8. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
9. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
10. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008
11. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... YORK , February 23, 2017 ... states have legalized cannabis for recreational use in 2016. According ... legal cannabis market was worth an estimated $7.2 billion in ... growth rate of 17%. While adult recreational sales are projected ... by 2020, with a 25% CAGR. The market may grow ...
(Date:2/23/2017)... , Feb. 22, 2017 This report analyzes analyzes ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2015 through ... markets. Market data and analytics are derived from primary and ...
(Date:2/23/2017)... DEERFIELD, Ill. , Feb. 23, 2017 ... Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited ... Cambridge Cognition Holdings PLC and Ctrl Group Limited, announced ... designed app on an Apple Watch wearable to monitor ... Disorder (MDD). Depression (MDD) is the leading ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... (PRWEB) February 23, ... the nation to come together to combine its favorite springtime ... its favorite fruit – apples! To celebrate National Nutrition Month, ... the “Apple Madness” bracket tournament – a five-week, five-round online ...
(Date:2/23/2017)... ... 2017 , ... Top cosmetic and periodontal dentist Dr. Mahnaz Rashti ... Indiegogo campaign . Individuals are now able to contribute to the local initiative, ... as a participating patient or through an Indiegogo donation. The entirety of proceeds will ...
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for standing designer ... stand solutions representative to the Minneapolis Home and Garden Show which is being held ... is garnering national attention is the Minneapolis Convention Center. , From its broad ...
(Date:2/23/2017)... FALLS CHURCH, Va. (PRWEB) , ... February 23, 2017 , ... ... , worries, or problems. He has also continued to spiritually evolve, which is the ... his published book “ Our Spiritual Truths ” (published by Balboa Press) attempts to ...
(Date:2/22/2017)... ... February 22, 2017 , ... Our high-octane society demands ... the sharpest brain. , Power On, a mental performance enhancer from Modus Nutrition, ... brain. Each capsule contains Cognizin® Citicoline, a branded form of the brain health ...
Breaking Medicine News(10 mins):